Droxidopa
| Evidence Level: L5 | Predicted Indications: 1 |
Table of Contents
- Droxidopa
- Droxidopa: From Neurogenic Orthostatic Hypotension to Variably Protease-Sensitive Prionopathy
Droxidopa: From Neurogenic Orthostatic Hypotension to Variably Protease-Sensitive Prionopathy
One-Sentence Summary
Droxidopa is an oral prodrug of norepinephrine, used for symptomatic neurogenic orthostatic hypotension. The TxGNN model predicts it may be effective for variably protease-sensitive prionopathy (VPSPr), a rare prion disease. Currently there are 0 clinical trials and 0 publications supporting this direction, so it is a model prediction only.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Neurogenic orthostatic hypotension (US label indication text is not included in the data provided) |
| Predicted New Indication | Variably protease-sensitive prionopathy |
| TxGNN Prediction Score | 99.33% |
| Evidence Level | L5 |
| US Market Status | ✓ Marketed |
| Number of NDAs | 20 (the five listed are ANDA generics) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the Evidence Pack. Droxidopa is known to be converted by DOPA decarboxylase into norepinephrine. That supports its use in neurogenic orthostatic hypotension, where it raises blood pressure symptomatically.
VPSPr is a rare sporadic prion disease driven by misfolded prion protein aggregation and neurodegeneration. Norepinephrine replacement does not address prion misfolding, propagation, or clearance. No credible mechanistic link between droxidopa and VPSPr has been identified.
The high score (0.993) most likely reflects proximity in the knowledge graph, such as shared neurological or neurodegenerative neighbours, rather than a validated biological rationale. At most, droxidopa might relieve autonomic symptoms in affected patients. It would not modify the disease. Similarity to the original indication and route compatibility have not been assessed.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
US Market Information
| Authorization Number | Product Name | Dosage Form | Manufacturer |
|---|---|---|---|
| ANDA211652 | Droxidopa | Capsule | Lupin Pharmaceuticals, Inc. |
| ANDA214387 | Droxidopa | Capsule | Aurobindo Pharma Limited |
| ANDA211818 | Droxidopa | Capsule | Zydus Lifesciences Limited |
| ANDA214017 | Droxidopa | Capsule | ScieGen Pharmaceuticals Inc |
| ANDA213911 | Droxidopa | Capsule | Ascend Laboratories, LLC |
The five authorizations above are the main ones of 20 in total. All are oral capsules. Approved indication text was not available for any of them.
Safety Considerations
Please refer to the package insert for safety information. No drug interaction records were found in the queried source.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests on the model score alone, with no trials, no literature, and no credible mechanistic link. Droxidopa’s norepinephrine-based action does not target prion pathology, so the high score is unlikely to reflect a real therapeutic opportunity.
To proceed, the following is needed:
- Package insert warnings and contraindications (a blocking gap for safety screening)
- Mechanism of action data from DrugBank, to cross-check the mechanistic assessment
- Any preclinical or clinical evidence linking noradrenergic therapy to prion disease outcomes
- A clearly defined symptomatic-benefit hypothesis (for example, autonomic dysfunction in VPSPr) if the direction is pursued
This report is for research reference only and does not constitute medical advice. Repurposing candidates require clinical validation before any application.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.